Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.38
(0.0%)
CNY 2.38
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - CNY | 0.0% |
| 2022 | - CNY | 0.0% |
| 2021 | - CNY | -100.0% |
| 2020 | 10.93 Million CNY | 757.72% |
| 2019 | 1.27 Million CNY | -99.87% |
| 2018 | 996.76 Million CNY | -31.52% |
| 2017 | 1.45 Billion CNY | 49.62% |
| 2016 | 972.76 Million CNY | 224.26% |
| 2015 | 300 Million CNY | -10.9% |
| 2014 | 336.7 Million CNY | 2290.96% |
| 2013 | -15.36 Million CNY | -202.45% |
| 2012 | 15 Million CNY | -50.0% |
| 2011 | 30 Million CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | -100.0% |
| 2007 | 1.07 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 19 Million CNY | 0.0% |
| 2024 Q2 | 32.53 Million CNY | 71.24% |
| 2024 Q3 | 8.5 Million CNY | -73.86% |
| 2023 Q3 | - CNY | 0.0% |
| 2023 Q4 | - CNY | 0.0% |
| 2023 FY | - CNY | 0.0% |
| 2023 Q1 | 1.00 CNY | 0.0% |
| 2023 Q2 | - CNY | -100.0% |
| 2022 Q3 | 1.00 CNY | 0.0% |
| 2022 FY | - CNY | 0.0% |
| 2022 Q4 | - CNY | -100.0% |
| 2022 Q2 | 1.00 CNY | 0.0% |
| 2022 Q1 | 1.00 CNY | 0.0% |
| 2021 FY | - CNY | -100.0% |
| 2021 Q4 | - CNY | -100.0% |
| 2021 Q1 | 11.06 Million CNY | 0.0% |
| 2021 Q2 | 11.19 Million CNY | 1.18% |
| 2021 Q3 | 1.00 CNY | -100.0% |
| 2020 Q2 | 824.75 Thousand CNY | -16.51% |
| 2020 Q4 | - CNY | -100.0% |
| 2020 FY | 10.93 Million CNY | 757.72% |
| 2020 Q1 | 987.87 Thousand CNY | -22.52% |
| 2020 Q3 | 825.15 Thousand CNY | 0.05% |
| 2019 Q1 | 997.47 Million CNY | 0.07% |
| 2019 FY | 1.27 Million CNY | -99.87% |
| 2019 Q4 | 1.27 Million CNY | -99.74% |
| 2019 Q3 | 499.42 Million CNY | 0.07% |
| 2019 Q2 | 499.07 Million CNY | -49.97% |
| 2018 Q4 | 996.76 Million CNY | -32.01% |
| 2018 Q3 | 1.46 Billion CNY | 0.49% |
| 2018 FY | 996.76 Million CNY | -31.52% |
| 2018 Q1 | 1.45 Billion CNY | -0.37% |
| 2018 Q2 | 1.45 Billion CNY | 0.61% |
| 2017 Q4 | 1.45 Billion CNY | -25.64% |
| 2017 FY | 1.45 Billion CNY | 49.62% |
| 2017 Q1 | 1.66 Billion CNY | 71.03% |
| 2017 Q2 | 1.96 Billion CNY | 17.88% |
| 2017 Q3 | 1.95 Billion CNY | -0.2% |
| 2016 Q2 | 961 Million CNY | 20.13% |
| 2016 Q1 | 800 Million CNY | 166.67% |
| 2016 Q4 | 972.76 Million CNY | 1.22% |
| 2016 Q3 | 961 Million CNY | 0.0% |
| 2016 FY | 972.76 Million CNY | 224.26% |
| 2015 Q1 | 313.14 Million CNY | -7.0% |
| 2015 FY | 300 Million CNY | -10.9% |
| 2015 Q3 | 456.54 Million CNY | 45.79% |
| 2015 Q4 | 300 Million CNY | -34.29% |
| 2015 Q2 | 313.14 Million CNY | 0.0% |
| 2014 Q4 | 336.7 Million CNY | -20.48% |
| 2014 Q3 | 423.44 Million CNY | 25.76% |
| 2014 FY | 336.7 Million CNY | 2290.96% |
| 2014 Q1 | - CNY | 100.0% |
| 2014 Q2 | 336.7 Million CNY | 0.0% |
| 2013 Q2 | 10 Million CNY | -33.33% |
| 2013 Q4 | -15.36 Million CNY | 0.0% |
| 2013 FY | -15.36 Million CNY | -202.45% |
| 2013 Q1 | 15 Million CNY | 0.0% |
| 2013 Q3 | - CNY | -100.0% |
| 2012 Q4 | 15 Million CNY | -45.45% |
| 2012 FY | 15 Million CNY | -50.0% |
| 2012 Q3 | 27.5 Million CNY | 0.0% |
| 2012 Q2 | 27.5 Million CNY | -8.33% |
| 2012 Q1 | 30 Million CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2011 Q4 | 30 Million CNY | 0.0% |
| 2011 FY | 30 Million CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2010 Q3 | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2010 Q1 | - CNY | 0.0% |
| 2009 Q4 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2008 FY | - CNY | -100.0% |
| 2007 FY | 1.07 Million CNY | 0.0% |